Aging Fat Cells Release Asprosin, Pushing Blood Vessel Cells Into Senescence
Asprosin from aging fat cells damages mitochondria in vessel-lining cells and triggers senescence via STING. Blocking it protected mice.
Summary
Vascular aging may be driven partly by a hormone released from fat cells. Researchers found that asprosin, a metabolic regulator secreted by adipocytes, rises with aging and cellular senescence in human endothelial cells (the cells lining blood vessels) and in mice. In mice aged artificially with D-galactose, an anti-asprosin antibody lowered senescence markers and inflammatory signals. Mice that could not make asprosin were also protected from vessel wall thickening and collagen buildup. Injecting asprosin into mice reproduced much of the damage, including thicker vessel walls and higher systolic blood pressure. In cell experiments, asprosin damaged mitochondria, made them fragment, and caused mitochondrial DNA to leak into the cell's interior. That leak activated the STING pathway, which promoted senescence. Scavenging mitochondrial reactive oxygen species or knocking down STING reduced the effects. The work is preclinical, but it points to asprosin as a possible target for protecting blood vessels from aging.
Detailed Summary
Blood vessels age in part because senescent cells release inflammatory signals, known as the senescence-associated secretory phenotype (SASP), into the bloodstream, where endothelial cells readily absorb them. No known intervention directly shields these cells from this process. A new study points to a possible culprit and target: asprosin, a metabolic regulator secreted by fat cells.
Researchers found asprosin was significantly upregulated in senescent human endothelial cells and in aging wild-type mice. In mice aged rapidly with D-galactose, an anti-asprosin antibody reduced senescence biomarkers and inflammatory cytokines. Mice injected with asprosin showed similar inflammatory and senescence profiles to the D-galactose mice, along with thickened vessel walls and higher systolic blood pressure. Mice genetically unable to produce asprosin were also protected from D-galactose-driven inflammation, vessel thickening and collagen accumulation.
The mechanism appears to run through mitochondria. Asprosin damaged mitochondrial membranes and caused fragmentation, much like hydrogen peroxide, and the two together were worse. It also caused mitochondrial DNA to leak into the cytosol, a known trigger of the cGAS-STING pathway. This was linked to increased mitochondrial reactive oxygen species. Knocking down STING prevented the resulting senescence, and mitoTEMPO, a scavenger of mitochondrial ROS, mitigated many of the effects. Conditioned media from adipocytes lacking asprosin was healthier for endothelial cells, improving proliferation and migration and blunting hydrogen peroxide-induced senescence.
Practically, this suggests that fat tissue may contribute directly to vascular aging, and that asprosin, mitochondrial protection or STING signaling could become therapeutic targets. Nothing here is yet an intervention readers can use, though it adds to the case for managing excess adiposity.
Several caveats apply. The data come from mice and cultured cells. D-galactose is an imperfect model of natural aging. The antibody did not fix impaired vessel dilation, so benefits were partial. Human validation and safety testing are still needed.
Key Findings
- Asprosin rises with senescence in human endothelial cells and with aging in mice.
- Anti-asprosin antibody lowered senescence and inflammation markers in D-galactose-aged mice.
- Asprosin-deficient mice were protected from vessel thickening and collagen accumulation.
- Asprosin drives mtDNA leakage and STING activation; blocking STING prevented senescence in cells.
- The antibody did not restore impaired vessel dilation, so protection was partial.
Methodology
This is a news-style research summary from Lifespan.io of a preclinical study using mice, D-galactose aging models and cultured human endothelial cells. Lifespan.io is a reputable longevity outlet, but this is secondary reporting. The evidence is mechanistic and animal-based.
Study Limitations
Findings are from mice and cells, and D-galactose only partly mimics natural aging. The article is truncated and secondary, so check the original paper for effect sizes, methods and statistics. Human relevance and safety of targeting asprosin remain unproven.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
